HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase

Brian M. Olson, Thomas P. Frye, Laura E. Johnson, Lawrence Fong, Keith L Knutson, Mary L. Disis, Douglas G. McNeel

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Prostatic acid phosphatase (PAP) has been investigated as the target of several antigen-specific anti-prostate tumor vaccines. The goal of antigen-specific active immunotherapies targeting PAP would ideally be to elicit PAP-specific CD8+ effector T cells. The identification of PAP-specific CD8+ T-cell epitopes should provide a means of monitoring the immunological efficacy of vaccines targeting PAP, and these epitopes might themselves be developed as vaccine antigens. In the current report, we hypothesized that PAP-specific epitopes might be identified by direct identification of pre-existing CD8+ T cells specific for HLA-A2-restricted peptides derived from PAP in the blood of HLA-A2-expressing individuals. 11 nonamer peptides derived from the amino acid sequence of PAP were used as stimulator antigens in functional ELISPOT assays with peripheral blood mononuclear cells from 20 HLA-A2+ patients with prostate cancer or ten healthy blood donors. Peptide-specific T cells were frequently identified in both groups for three of the peptides, p18-26, p112-120, and p135-143. CD8+ T-cell clones specific for three peptides, p18-26, p112-120, and p299-307, confirmed that these are HLA-A2-restricted T-cell epitopes. Moreover, HLA-A2 transgenic mice immunized with a DNA vaccine encoding PAP developed epitope-specific responses for one or more of these three peptide epitopes. We propose that this method to first identify epitopes for which there are pre-existing epitope-specific T cells could be used to prioritize MHC class I-specific epitopes for other antigens. In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses.

Original languageEnglish (US)
Pages (from-to)943-953
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume59
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

HLA-A2 Antigen
T-Lymphocyte Epitopes
Epitopes
Peptides
T-Lymphocytes
Antigens
Vaccines
prostatic acid phosphatase
Peptide T
Enzyme-Linked Immunospot Assay
Immunologic Monitoring
Active Immunotherapy
Cancer Vaccines
DNA Vaccines
Prostate-Specific Antigen
Blood Donors
Transgenic Mice
Amino Acid Sequence
Blood Cells
Prostatic Neoplasms

Keywords

  • CTL
  • ELISPOT
  • Epitope
  • HLA-A2
  • Prostatic acid phosphatase (PAP)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Olson, B. M., Frye, T. P., Johnson, L. E., Fong, L., Knutson, K. L., Disis, M. L., & McNeel, D. G. (2010). HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunology, Immunotherapy, 59(6), 943-953. https://doi.org/10.1007/s00262-010-0820-6

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. / Olson, Brian M.; Frye, Thomas P.; Johnson, Laura E.; Fong, Lawrence; Knutson, Keith L; Disis, Mary L.; McNeel, Douglas G.

In: Cancer Immunology, Immunotherapy, Vol. 59, No. 6, 06.2010, p. 943-953.

Research output: Contribution to journalArticle

Olson, BM, Frye, TP, Johnson, LE, Fong, L, Knutson, KL, Disis, ML & McNeel, DG 2010, 'HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase', Cancer Immunology, Immunotherapy, vol. 59, no. 6, pp. 943-953. https://doi.org/10.1007/s00262-010-0820-6
Olson, Brian M. ; Frye, Thomas P. ; Johnson, Laura E. ; Fong, Lawrence ; Knutson, Keith L ; Disis, Mary L. ; McNeel, Douglas G. / HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. In: Cancer Immunology, Immunotherapy. 2010 ; Vol. 59, No. 6. pp. 943-953.
@article{91bb9d088ece4da693112c299c24b47c,
title = "HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase",
abstract = "Prostatic acid phosphatase (PAP) has been investigated as the target of several antigen-specific anti-prostate tumor vaccines. The goal of antigen-specific active immunotherapies targeting PAP would ideally be to elicit PAP-specific CD8+ effector T cells. The identification of PAP-specific CD8+ T-cell epitopes should provide a means of monitoring the immunological efficacy of vaccines targeting PAP, and these epitopes might themselves be developed as vaccine antigens. In the current report, we hypothesized that PAP-specific epitopes might be identified by direct identification of pre-existing CD8+ T cells specific for HLA-A2-restricted peptides derived from PAP in the blood of HLA-A2-expressing individuals. 11 nonamer peptides derived from the amino acid sequence of PAP were used as stimulator antigens in functional ELISPOT assays with peripheral blood mononuclear cells from 20 HLA-A2+ patients with prostate cancer or ten healthy blood donors. Peptide-specific T cells were frequently identified in both groups for three of the peptides, p18-26, p112-120, and p135-143. CD8+ T-cell clones specific for three peptides, p18-26, p112-120, and p299-307, confirmed that these are HLA-A2-restricted T-cell epitopes. Moreover, HLA-A2 transgenic mice immunized with a DNA vaccine encoding PAP developed epitope-specific responses for one or more of these three peptide epitopes. We propose that this method to first identify epitopes for which there are pre-existing epitope-specific T cells could be used to prioritize MHC class I-specific epitopes for other antigens. In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses.",
keywords = "CTL, ELISPOT, Epitope, HLA-A2, Prostatic acid phosphatase (PAP)",
author = "Olson, {Brian M.} and Frye, {Thomas P.} and Johnson, {Laura E.} and Lawrence Fong and Knutson, {Keith L} and Disis, {Mary L.} and McNeel, {Douglas G.}",
year = "2010",
month = "6",
doi = "10.1007/s00262-010-0820-6",
language = "English (US)",
volume = "59",
pages = "943--953",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase

AU - Olson, Brian M.

AU - Frye, Thomas P.

AU - Johnson, Laura E.

AU - Fong, Lawrence

AU - Knutson, Keith L

AU - Disis, Mary L.

AU - McNeel, Douglas G.

PY - 2010/6

Y1 - 2010/6

N2 - Prostatic acid phosphatase (PAP) has been investigated as the target of several antigen-specific anti-prostate tumor vaccines. The goal of antigen-specific active immunotherapies targeting PAP would ideally be to elicit PAP-specific CD8+ effector T cells. The identification of PAP-specific CD8+ T-cell epitopes should provide a means of monitoring the immunological efficacy of vaccines targeting PAP, and these epitopes might themselves be developed as vaccine antigens. In the current report, we hypothesized that PAP-specific epitopes might be identified by direct identification of pre-existing CD8+ T cells specific for HLA-A2-restricted peptides derived from PAP in the blood of HLA-A2-expressing individuals. 11 nonamer peptides derived from the amino acid sequence of PAP were used as stimulator antigens in functional ELISPOT assays with peripheral blood mononuclear cells from 20 HLA-A2+ patients with prostate cancer or ten healthy blood donors. Peptide-specific T cells were frequently identified in both groups for three of the peptides, p18-26, p112-120, and p135-143. CD8+ T-cell clones specific for three peptides, p18-26, p112-120, and p299-307, confirmed that these are HLA-A2-restricted T-cell epitopes. Moreover, HLA-A2 transgenic mice immunized with a DNA vaccine encoding PAP developed epitope-specific responses for one or more of these three peptide epitopes. We propose that this method to first identify epitopes for which there are pre-existing epitope-specific T cells could be used to prioritize MHC class I-specific epitopes for other antigens. In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses.

AB - Prostatic acid phosphatase (PAP) has been investigated as the target of several antigen-specific anti-prostate tumor vaccines. The goal of antigen-specific active immunotherapies targeting PAP would ideally be to elicit PAP-specific CD8+ effector T cells. The identification of PAP-specific CD8+ T-cell epitopes should provide a means of monitoring the immunological efficacy of vaccines targeting PAP, and these epitopes might themselves be developed as vaccine antigens. In the current report, we hypothesized that PAP-specific epitopes might be identified by direct identification of pre-existing CD8+ T cells specific for HLA-A2-restricted peptides derived from PAP in the blood of HLA-A2-expressing individuals. 11 nonamer peptides derived from the amino acid sequence of PAP were used as stimulator antigens in functional ELISPOT assays with peripheral blood mononuclear cells from 20 HLA-A2+ patients with prostate cancer or ten healthy blood donors. Peptide-specific T cells were frequently identified in both groups for three of the peptides, p18-26, p112-120, and p135-143. CD8+ T-cell clones specific for three peptides, p18-26, p112-120, and p299-307, confirmed that these are HLA-A2-restricted T-cell epitopes. Moreover, HLA-A2 transgenic mice immunized with a DNA vaccine encoding PAP developed epitope-specific responses for one or more of these three peptide epitopes. We propose that this method to first identify epitopes for which there are pre-existing epitope-specific T cells could be used to prioritize MHC class I-specific epitopes for other antigens. In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses.

KW - CTL

KW - ELISPOT

KW - Epitope

KW - HLA-A2

KW - Prostatic acid phosphatase (PAP)

UR - http://www.scopus.com/inward/record.url?scp=77953114986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953114986&partnerID=8YFLogxK

U2 - 10.1007/s00262-010-0820-6

DO - 10.1007/s00262-010-0820-6

M3 - Article

VL - 59

SP - 943

EP - 953

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -